BC Extra | May 22, 2018
Company News

Management tracks: Trevena, Galecto

Neurology company Trevena Inc. (NASDAQ:TRVN) hired Mark Demitrack as SVP and CMO. He was VP of clinical strategy at Roivant Sciences GmbH (Basel, Switzerland). Galectin modulator company Galecto Biotech AB (Copenhagen, Denmark) hired Richard Marshall...
BC Week In Review | Mar 31, 2017
Company News

Icagen, Bayer deal

Icagen and Bayer partnered for up to two years to develop new X-ray fluorescence assays using Icagen’s XRpro platform. The new assays will help Bayer progress its discovery programs for transporter targets and high throughput...
BC Week In Review | Aug 10, 2015
Company News

Pfizer, XRpro deal

XRpro acquired from Pfizer assets related to the ion channel biology platform the pharma obtained in its 2011 acquisition of Icagen Inc. The purchase includes Pfizer’s rights to the “Icagen” name and trademark. XRpro relaunched...
BC Week In Review | Jan 12, 2015
Financial News

XRpro completes private placement of units

XRpro Sciences Inc. , Cambridge, Mass.   Business: Supply/Service   Date completed: 2015-01-08   Type: Private placement of units   Raised: $8.9 million   Units: 1.3 million   Price: $7 (unit)   Shares after offering: 5.3...
BC Week In Review | Apr 15, 2013
Company News

Icagen, Bristol-Myers deal

The companies will discover and develop small molecule compounds targeting ion channels involved in atrial fibrillation, an irregular heart beat resulting from abnormal electrical signaling to cardiac muscle. The collaboration will focus on an ion...
BC Week In Review | Apr 15, 2013
Company News

Icagen board of directors update

ICAgen Inc., Research Triangle Park, N.C.   Business: Drug discovery   Appointed: Dennis Gillings, Ph.D., chairman and CEO of Quintiles Transnational Corp.  ...
BC Week In Review | Apr 15, 2013
Company News

Icagen other research news

ICAgen received a $590,000 Phase II SBIR grant from the National Institute of General Medical Sciences to further develop assays that detect drug action at ion channels. Rapid expression cloning of new channel isoforms is...
BC Week In Review | Mar 12, 2012
Company News

Viamet management update

Viamet Pharmaceuticals Inc. , Morrisville, N.C.   Business: Infectious, Cancer   Hired: Richard Katz as CBO and CFO, a newly created position, formerly EVP of finance and corporate development and CFO of Icagen Inc. , which Pfizer...
BC Week In Review | Nov 7, 2011
Company News

Icagen, Pfizer deal

Pfizer completed its acquisition of Icagen, which will become a wholly-owned subsidiary of Pfizer. Icagen will be integrated into Pfizer's Neusentis research unit for pain, sensory disorders and regenerative medicine (see BioCentury, July 25 &...
BC Week In Review | Sep 26, 2011
Company News

Icagen, Pfizer deal

Pfizer completed its subsequent tender offer to acquire the remaining shares of Icagen, acquiring 5.4 million shares at $6 per share in cash, or about $32.4 million. The tender, when combined with Pfizer's existing 1.1...
Items per page:
1 - 10 of 171
BC Extra | May 22, 2018
Company News

Management tracks: Trevena, Galecto

Neurology company Trevena Inc. (NASDAQ:TRVN) hired Mark Demitrack as SVP and CMO. He was VP of clinical strategy at Roivant Sciences GmbH (Basel, Switzerland). Galectin modulator company Galecto Biotech AB (Copenhagen, Denmark) hired Richard Marshall...
BC Week In Review | Mar 31, 2017
Company News

Icagen, Bayer deal

Icagen and Bayer partnered for up to two years to develop new X-ray fluorescence assays using Icagen’s XRpro platform. The new assays will help Bayer progress its discovery programs for transporter targets and high throughput...
BC Week In Review | Aug 10, 2015
Company News

Pfizer, XRpro deal

XRpro acquired from Pfizer assets related to the ion channel biology platform the pharma obtained in its 2011 acquisition of Icagen Inc. The purchase includes Pfizer’s rights to the “Icagen” name and trademark. XRpro relaunched...
BC Week In Review | Jan 12, 2015
Financial News

XRpro completes private placement of units

XRpro Sciences Inc. , Cambridge, Mass.   Business: Supply/Service   Date completed: 2015-01-08   Type: Private placement of units   Raised: $8.9 million   Units: 1.3 million   Price: $7 (unit)   Shares after offering: 5.3...
BC Week In Review | Apr 15, 2013
Company News

Icagen, Bristol-Myers deal

The companies will discover and develop small molecule compounds targeting ion channels involved in atrial fibrillation, an irregular heart beat resulting from abnormal electrical signaling to cardiac muscle. The collaboration will focus on an ion...
BC Week In Review | Apr 15, 2013
Company News

Icagen board of directors update

ICAgen Inc., Research Triangle Park, N.C.   Business: Drug discovery   Appointed: Dennis Gillings, Ph.D., chairman and CEO of Quintiles Transnational Corp.  ...
BC Week In Review | Apr 15, 2013
Company News

Icagen other research news

ICAgen received a $590,000 Phase II SBIR grant from the National Institute of General Medical Sciences to further develop assays that detect drug action at ion channels. Rapid expression cloning of new channel isoforms is...
BC Week In Review | Mar 12, 2012
Company News

Viamet management update

Viamet Pharmaceuticals Inc. , Morrisville, N.C.   Business: Infectious, Cancer   Hired: Richard Katz as CBO and CFO, a newly created position, formerly EVP of finance and corporate development and CFO of Icagen Inc. , which Pfizer...
BC Week In Review | Nov 7, 2011
Company News

Icagen, Pfizer deal

Pfizer completed its acquisition of Icagen, which will become a wholly-owned subsidiary of Pfizer. Icagen will be integrated into Pfizer's Neusentis research unit for pain, sensory disorders and regenerative medicine (see BioCentury, July 25 &...
BC Week In Review | Sep 26, 2011
Company News

Icagen, Pfizer deal

Pfizer completed its subsequent tender offer to acquire the remaining shares of Icagen, acquiring 5.4 million shares at $6 per share in cash, or about $32.4 million. The tender, when combined with Pfizer's existing 1.1...
Items per page:
1 - 10 of 171